J
Janet E. Price
Researcher at University of Texas MD Anderson Cancer Center
Publications - 122
Citations - 8550
Janet E. Price is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Metastasis & Cancer. The author has an hindex of 48, co-authored 122 publications receiving 8221 citations. Previous affiliations of Janet E. Price include University of Texas at Austin & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Retention of "metastatic" colonisation potential by cells of spontaneous primary tumours after cryopreservation.
Janet E. Price,David Tarin +1 more
TL;DR: Retention of “metastatic” colonisation potential by cells of spontaneous primary tumours after cryopreservation is studied in mice models of leukaemia.
Journal ArticleDOI
Tumorigenicity and metastatic behavior in nude mice of two human squamous cell carcinoma lines that differ in production of the cytokine ETAF/IL-1
TL;DR: It is concluded that while the growth and metastasis of human SCC in nude mice may benefit from production of the cytokine ETAF, the EtaF production per se is not invariably linked with the capability of the SCC cells to metastasize.
Journal ArticleDOI
Therapeutic intervention with breast cancer metastasis.
Dina Lev,Janet E. Price +1 more
TL;DR: The identification of molecular targets for therapy of breast cancer metastasis will be accelerated by DNA array technology, and their selection for use should include evaluation of interactions between tumor cells and normal tissue components.
Journal ArticleDOI
Lectin agglutinability of mammary tumours with differing metastatic colonisation potentials.
Janet E. Price,David Tarin +1 more
TL;DR: It was found that agglutinability with the lectins Concanavalin-A and Wheatgerm agglUTinin bore no relationship to the pulmonary colonisation potential of the primary mammary tumour.
Journal ArticleDOI
Molecular profile of advanced-stage transitional cell carcinoma of the ovary ☆ ☆☆ ★
David M. Gershenson,Vicki V. Baker,Janet E. Price,Mien Chie Hung,Adel K. El-Naggar,Guillermo Tortolero-Luna,Elvio G. Silva +6 more
TL;DR: Neither immunostaining for p53, epidermal growth factor receptor, and HER-2/neu nor deoxyribonucleic acid ploidy nor S-phase fraction allowed us to distinguish transitional cell carcinoma from other more common epithelial ovarian cancers.